Nova Southeastern University Researchers Receive $4 Million From CDC for ‘COVID Long Haulers’ Study

Many COVID-19 Patients Suffering Long-Lasting Effects After Recovery – NSU Only Institution to Receive This Grant to Begin New Study
Nova Southeastern University
28-Oct-2020 11:30 AM EDT, by Nova Southeastern University

Newswise — FORT LAUDERDALE/DAVIE, Fla. – As the COVID-19 pandemic continues to evolve, health care providers are finding more and more patients are experiencing lingering symptoms after recovering from the virus. These symptoms can vary from being bone-tired, utterly exhausted, or drained of energy , but in most cases they continue to negatively impact the patient’s overall well-being and ability to return to normal activities. While the medical community is still working hard to address the virus itself and racing toward a vaccine, there is very little known or being done to address these residual health issues being experienced by those now called “COVID long haulers.”

But all of that is about to change, thanks to research scientists at Nova Southeastern University (NSU.) 

“With our long-standing research into ME/Chronic Fatigue Syndrome, we’ve been selected by the Centers for Disease Control and Prevention to begin researching these symptoms in COVID-19 patients,” said Nancy Klimas, M.D. “Because the symptoms are so similar – joint and muscle pain, severe fatigue and memory and cognitive issues – to Chronic Fatigue Syndrome, NSU is uniquely positioned to study this emerging development in the pandemic.”

With more than 30 years of professional experience, Dr. Klimas has achieved international recognition for her research and clinical efforts in multi-symptom disorders, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), Gulf War illness (GWI), fibromyalgia and other neuro-immune disorders. Because of her expertise and the work she is involved with at the university, the CDC has awarded NSU a federal contract of more than $4 million to study these residual symptoms in COVID-19 patients.

NSU is the only institution to receive this federal contract. 

Dr. Klimas, who is also the Director of NSU’s Institute for Neuro-Immune Medicine, said that similar symptoms were identified in patients after other viral infections, such as the severe acute respiratory syndrome (SARS) outbreak in 2003. Over the years, patients suffering from these symptoms were given a variety of treatments, including respiratory, cardiovascular and physical therapy. Unfortunately, it’s not a one-size-fits-all situation, and in some cases, existing therapies can actually make the patient worse.

That’s why this research is so important – with COVID-19 so widespread, there are going to be thousands upon thousands of long-haulers who are going to need help.

For this research study, NSU will work with the Florida Department of Health to identify potential participants. NSU researchers then will contact individuals to describe the study and to ask their interest and permission to be participate in the study. As you can imagine, this list is quite extensive – more than 40,000 patients and counting. In addition, NSU is working with partner health care providers, such as Community Health of South Florida, Inc. in Miami, to identify other patients. So between both pools of participants, NSU researchers want to have 2,200 individuals agree and opt in for the study.

“One of the things we want to ensure is that our group of participants is truly a diverse sample of people who are affected by this new syndrome,” said Nicole Cook, Ph.D., MPA, an associate professor of public health at NSU. “We hope to engage members of underserved communities, including minorities, who have been disproportionately impacted by COVID-19 and therefore will likely have a higher  number of ‘long haulers’.”

Cook said that the group will participate in various on-going online surveys to collect data, with a smaller sub-group (approximately 200) participating in clinic-based assessments. Regardless of which aspect of the study they are involved with, this research will not impact or impede any ongoing health care they may be receiving to treat their symptoms.

Along with Drs. Klimas and Cook, others on the NSU research team include Drs. Irma Rey and Alison Bested and nurse practitioners Drs. Violeta Renesca and Irina Rozenfeld.

“We need to understand and describe this new disease and we’re still in the early stages of learning about it,” said Klimas. “This study will provide the chance to see patients early on in their conditions, and that’s vital for development treatments.”


Be sure to sign up for NSU’s RSS feed so you don’t miss any of our news releases, guest editorials and other announcements. Please sign up HERE. You can also follow us on Twitter @NSUNews.




About Nova Southeastern University (NSU): At NSU, students don’t just get an education, they get the competitive edge they need for real careers, real contributions and real life. A dynamic, private research university, NSU is providing high-quality educational and research programs at the undergraduate, graduate, and professional degree levels. Established in 1964, the university includes 15 colleges, the 215,000-square-foot Center for Collaborative Research, the private JK-12 grade University School, the world-class NSU Art Museum Fort Lauderdale, and the Alvin Sherman Library, Research and Information Technology Center, one of Florida’s largest public libraries. NSU students learn at our campuses in Fort Lauderdale, Fort Myers, Jacksonville, Miami, Miramar, Orlando, Palm Beach, and Tampa, Florida, as well as San Juan, Puerto Rico, and online globally. With nearly 200,000 alumni across the nation and globe, the reach of the NSU community is worldwide.  Classified as having “high research activity” by the Carnegie Foundation for the Advancement of Teaching, NSU is one of only 50 universities nationwide to also be awarded Carnegie’s Community Engagement Classification, and is also the largest private institution in the United States that meets the U.S. Department of Education’s criteria as a Hispanic-serving Institution. Please visit for more information.

Filters close

Showing results

110 of 4156
Newswise: Stimulus Relief Funds Increase Social Distancing to Stop Spread of COVID-19
23-Nov-2020 5:20 PM EST
Stimulus Relief Funds Increase Social Distancing to Stop Spread of COVID-19
University of California San Diego

As case rates of COVID-19 reach new heights across the nation, many states and cities are tightening stay-at-home restrictions to stop the spread. New research suggests that that those suffering from economic hardships are less likely comply with new stay-at-home orders; however these same U.S. residents would be more likely to adhere to the new public health guidelines if their households received stimulus funds.

access_time Embargo lifts in 2 days
Embargo will expire: 1-Dec-2020 9:15 AM EST Released to reporters: 30-Nov-2020 2:30 PM EST

A reporter's PressPass is required to access this story until the embargo expires on 1-Dec-2020 9:15 AM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise:Video Embedded covid-19-update-surge-preparedness-vaccine-distribution
Released: 30-Nov-2020 2:20 PM EST
COVID-19 Update: Surge Preparedness, Vaccine Distribution

With the novel coronavirus spreading across the U.S. at a record pace, Cedars-Sinai has been seeing an increase in COVID-19 patients at its hospitals and through its network of physicians. But the health system's leaders say Cedars-Sinai is prepared.

Released: 30-Nov-2020 1:20 PM EST
Rethink COVID-19 infection control to keep primary schools open this winter, governments urged

An urgent rethink of infection control policies to keep COVID-19 infection at bay in schools is needed if primary schools are to be kept open this winter, and the knock-on effects on their families avoided, argue children's infectious disease specialists in a viewpoint, published online in the Archives of Disease in Childhood.

Newswise: Hackensack University Medical Center Urologists Continue to Provide State-of-the-Art Care During COVID-19
Released: 30-Nov-2020 12:45 PM EST
Hackensack University Medical Center Urologists Continue to Provide State-of-the-Art Care During COVID-19
Hackensack Meridian Health

Don’t Delay Your Care – Our dnhanced pandemic safety precautions prioritize patient health and allow providers to deliver outstanding in-office, telehealth and surgical care

Released: 30-Nov-2020 12:10 PM EST
Struggles of care home staff during COVID-19 first wave revealed in Whatsapp messages
University of Leeds

Analysis of social media messages between care home staff on the coronavirus front line reveal their growing concerns over how to manage in the face of the virus.

Released: 30-Nov-2020 11:30 AM EST
More than one-third of children with COVID-19 show no symptoms: study
University of Alberta Faculty of Medicine & Dentistry

More than one-third of kids who have COVID-19 are asymptomatic, according to a University of Alberta study that suggests youngsters diagnosed with the disease may represent just a fraction of those infected.

Newswise: Promising lab results in quest to find naturally occurring anti-COVID therapies
24-Nov-2020 5:35 PM EST
Promising lab results in quest to find naturally occurring anti-COVID therapies
University of Alabama Huntsville

So far, 35 of 125 naturally occurring compounds identified computationally at The University of Alabama in Huntsville (UAH) to have potential against COVID-19 have shown efficacy in ongoing first-batch testing at the University of Tennessee Health Science Center’s Regional Biocontainment Laboratory (UTHSC RBL) that’s the next step in the process to becoming a drug.

Released: 30-Nov-2020 9:45 AM EST
Rutgers Leading Coronavirus Therapeutic Clinical Trial
Rutgers University-New Brunswick

Rutgers is leading a clinical trial assessing the efficacy of a three-drug combination in treating people infected with SARS-CoV-2 and asymptomatic or mildly symptomatic.

Showing results

110 of 4156